Q-omics provides the consensus-scored RPL18A profile across patient tissues and cancer cell-line models. RPL18A expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL18A is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RPL18A protein abundance shows 25,195 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where RPL18A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL18A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL18A survival associations across molecular data types. RPL18A RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL18A RNA expression–survival associations across cancer types. High RPL18A expression shows unfavorable associations in ACC, KIRP, KICH, LIHC and THCA, but favorable associations in UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL18A RNA expression.
This table summarizes RPL18A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RPL18A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL18A shows higher tumor expression in KIRC, COAD, LIHC, KIRP, CHOL and LUSC. The KIRC box plot shows higher RPL18A RNA expression in tumor versus normal tissue (log2 FC = +1.209, t-test p < 0.001).
This table shows molecular features associated with RPL18A in patient tissues and cancer cell lines. In patient samples, RPL18A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL18A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
